DURECT Corporation Presenting at the HealthpointCapital Biomaterials Summit

Download PDF:

CUPERTINO, Calif., Oct. 12 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the HealthpointCapital
Biomaterials Summit. The conference is being held at the Omni Berkshire Place
in New York City, NY. Thomas A. Schreck, Chief Financial Officer, will be
presenting at the conference on Friday, October 15, 2004 at 1:15 p.m. EDT.

A live audio webcast of the presentation will be available by accessing
DURECT’s homepage at http://www.www.durect.com and clicking “Investor Relations.”

About DURECT Corporation

DURECT Corporation is a pharmaceutical company focused on the development
of pharmaceutical systems based on its proprietary drug delivery platform
technologies that treat chronic debilitating diseases and enable biotechnology
products. These platform technologies include the SABER(TM) Delivery System (a
patented and versatile depot injectable useful for protein and small molecule
delivery), the ORADUR(TM) sustained release oral gel-cap technology (an oral
sustained release technology with several potential abuse deterrent
properties), the DURIN(TM) Biodegradable Implant (drug-loaded implant system)
and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable
system). DURECT also partners with pharmaceutical companies to develop and
commercialize proprietary and enhanced pharmaceutical products based on its
technologies. DURECT has four disclosed on-going development programs of which
three are in collaboration with pharmaceutical partners. Additional
information about DURECT is available at www.www.durect.com.

NOTE: SABER(TM), ORADUR(TM), DURIN(TM) and MICRODUR(TM) are trademarks of
DURECT Corporation.

The statements in this press release regarding DURECT’s products in
development are forward-looking statements involving risks and uncertainties
that can cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties include, but are
not limited to, DURECT’s abilities to complete the design, development, and
manufacturing process development of these products, manufacture and
commercialize these products, obtain product and manufacturing approvals from
regulatory agencies as well as marketplace acceptance of these products.
Further information regarding these and other risks is included in DURECT’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2003 filed
with the SEC on March 11, 2004, DURECT’s Quarterly Report on Form 10-Q and
other periodic reports filed with the SEC under the heading “Factors that may
affect future results.”


/CONTACT: Schond L. Greenway, Executive Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840/
/Web site: http://www.www.durect.com/

Scroll to Top